摘要
目的:探讨急性移植物抗宿主病(aGVHD)患者miR-155的表达水平及其临床意义。方法:采用造血干细胞移植患者移植第0、第7、第14、第21及第28天的血浆标本,实时荧光定量PCR(qPCR)方法检测miR-155相对表达量,酶联免疫吸附试验(ELISA)法检测患者血浆中白细胞介素(IL)-4、IL-7、IL-10的含量。结果:miR-155在移植后第7天开始逐渐升高,到第28天时升高明显,患者移植后不同时间点miR-155相对表达量比较差异具有统计学意义(P<0.05)。allo-HSCT后不同时间点IL-4、IL-7、IL-10水平比较,差异均无统计学意义(P>0.05)。结论:allo-HSCT后miR-155较IL-4、IL-7、IL-10水平变化出现早,可作为早期诊断和预测a GVHD的无创性生物标记物。
Objective: To evaluate the expression and clinical significance of miR-155 in patients with acute graft-versus-host disease (aGVHD). Methods: miRNA was extracted from the plasma samples of patients day 0, day 7, day 14, day 21, day 28 after their hematopoietic stem cell transplantation(HSCT). The expressions of miR- 155, interleukin (IL) -4, IL-7 and IL- 10 were detected by qPCR. Results: The expression of miR- 155 obvi- ously increased on day 7 after HSCT, and reached the peak on day 28. The miR-155 expression level was in- creased with the prolonged time after transplantation (P〈0.05). There was no significant difference in the ex- pression of IL-4, IL-7 and IL-10 between any time points(P〉0. 05). Conclusion: MiR-155 might be a nonin- vasion biomarker for early detection of aGVHD, and the level of miR-155 changed earlier than IL-4, IL-10 and IL-7 after HSCT.
出处
《广西医科大学学报》
CAS
2017年第9期1292-1295,共4页
Journal of Guangxi Medical University
基金
深圳市知识创新计划基础研究项目(No.JCYJ20140414170821270)
深圳市骨髓移植技术临床应用公共服务平台项目(No.s2015003610009)